Results 1 to 10 of about 41,965 (298)

α7 Nicotinic Agonist AR-R17779 Protects Mice against 2,4,6-Trinitrobenzene Sulfonic Acid-Induced Colitis in a Spleen-Dependent Way [PDF]

open access: yesFrontiers in Pharmacology, 2017
The existence of a cholinergic anti-inflammatory pathway negatively modulating the inflammatory and immune responses in various clinical conditions and experimental models has long been postulated.
Andrea Grandi   +7 more
doaj   +2 more sources

Functional expression and properties of the tick α6 homomeric nicotinic acetylcholine receptor in Xenopus laevis oocytes [PDF]

open access: yesCurrent Research in Parasitology and Vector-Borne Diseases
Recent studies have suggested that the tick Ixodes ricinus expresses nAChR subtypes which are activated by acetylcholine. Here, we investigated the potential of the Iricα6 subunit to form a functional receptor when expressed in Xenopus laevis oocytes ...
Alison Cartereau   +3 more
doaj   +2 more sources

TC299423, a Novel Agonist for Nicotinic Acetylcholine Receptors [PDF]

open access: yesFrontiers in Pharmacology, 2017
(E)-5-(Pyrimidin-5-yl)-1,2,3,4,7,8-hexahydroazocine (TC299423) is a novel agonist for nicotinic acetylcholine receptors (nAChRs). We examined its efficacy, affinity, and potency for α6β2∗ (α6β2-containing), α4β2∗, and α3β4∗ nAChRs, using [125I ...
Teagan R. Wall   +12 more
doaj   +4 more sources

Alpha-7 nicotinic agonist improves cognition in schizophrenia. [PDF]

open access: yesEvid Based Ment Health, 2016
ABSTRACT FROM: Keefe RS, Meltzer HA, Dgetluck N, et al . Randomized, double-blind, placebo-controlled study of encenicline, an α7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology 2015;40:3053–60.
Marder SR.
europepmc   +3 more sources

Lynx1 and the family of endogenous mammalian neurotoxin-like proteins and their roles in modulating nAChR function

open access: yesPharmacological Research, 2023
The promise of nicotinic receptors as a therapeutic target has yet to be fully realized, despite solid data supporting their involvement in neurological and neuropsychiatric diseases.
Talulla B. Palumbo, Julie.M. Miwa
doaj   +1 more source

Nicotinic acetylcholine receptor agonists attenuate septic acute kidney injury in mice by suppressing inflammation and proteasome activity. [PDF]

open access: yesPLoS ONE, 2012
Sepsis is one of the leading causes of acute kidney injury (AKI). Septic patients who develop acute kidney injury (AKI) are at increased risk of death. To date there is no effective treatment for AKI or septic AKI.
Prodyot K Chatterjee   +6 more
doaj   +1 more source

The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia. [PDF]

open access: yesPLoS ONE, 2016
The development of alpha7 nicotinic acetylcholine receptor agonists is considered a promising approach for the treatment of cognitive symptoms in schizophrenia patients. In the present studies we characterized the novel agent, (2R)-N-(6-(1H-imidazol-1-yl)
Linda J Bristow   +22 more
doaj   +1 more source

Structural insights into the human niacin receptor HCA2-Gi signalling complex

open access: yesNature Communications, 2023
Hydroxyl-carboxylic acid receptor 2 (HCA2) functions as a high-affinity receptor for nicotinic acid (vitamin B3). Here, authors report the cryo-EM structure of the HCA2-Gi complex with the agonist MK-6892 and inactive state crystal structures of mutation
Yang Yang   +20 more
doaj   +1 more source

Nicotine receptor partial agonists for smoking cessation [PDF]

open access: yesSao Paulo Medical Journal, 2007
Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). Varenicline was developed as a nicotine receptor partial agonist from cytisine, a drug widely used in central
Cahill, Kate   +3 more
openaire   +17 more sources

Home - About - Disclaimer - Privacy